[
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Abemaciclib + Tamoxifen\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Tamoxifen\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Tamoxifen\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Anastrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Anastrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Anastrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Letrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Letrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Letrozole + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Fulvestrant + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Abemaciclib\nTherapy approach: Monotherapy\nTherapy strategy: CDK4/6 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib\nTherapy approach: Monotherapy\nTherapy strategy: CDK4/6 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib\nTherapy approach: Monotherapy\nTherapy strategy: CDK4/6 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BARD1 oncogenic variants [present]\nTherapy: Abiraterone acetate + Niraparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\nPublication date: 2023-08-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRIP1 oncogenic variants [present]\nTherapy: Abiraterone acetate + Niraparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\nPublication date: 2023-08-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRIP1 pathogenic variants [present]\nTherapy: Abiraterone acetate + Niraparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\nPublication date: 2023-08-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CDK12 pathogenic variants [present]\nTherapy: Abiraterone acetate + Niraparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\nPublication date: 2023-08-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to adagrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR), and that continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: KRAS p.G12C [present]\nTherapy: Adagrasib\nTherapy approach: Monotherapy\nTherapy strategy: RAS inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf\nPublication date: 2022-12-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Trastuzumab emtansine\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf\nPublication date: 2022-02-02",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Trastuzumab emtansine\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf\nPublication date: 2022-02-02",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to afatinib for the first-line treatment of patients with metastatic non-small lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR somatic variants [present]\nTherapy: Afatinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf\nPublication date: 2022-04-07",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Alectinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf\nPublication date: 2024-04-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Alectinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf\nPublication date: 2024-04-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PIK3CA somatic variants [present]\nTherapy: Alpelisib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf\nPublication date: 2024-01-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\nTherapy: Alpelisib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf\nPublication date: 2024-01-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\nTherapy: Alpelisib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf\nPublication date: 2024-01-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 20 (Insertion) [present]\nTherapy: Carboplatin + Pemetrexed + Amivantamab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Antifolate + EGFR inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\nPublication date: 2024-09-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to amivantamab-vmjw for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 20 (Insertion) [present]\nTherapy: Amivantamab\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\nPublication date: 2024-09-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.\nCancer type: APL with PML-RARA\nBiomarkers: PML::RARA [present]\nTherapy: Arsenic trioxide\nTherapy approach: Monotherapy\nTherapy strategy: PML::RARA inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf\nPublication date: 2020-10-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.\nCancer type: APL with PML-RARA\nBiomarkers: PML::RARA [present]\nTherapy: Arsenic trioxide\nTherapy approach: Monotherapy\nTherapy strategy: PML::RARA inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf\nPublication date: 2020-10-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Asciminib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\nPublication date: 2024-10-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present], ABL1 p.T315I [present]\nTherapy: Asciminib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\nPublication date: 2024-10-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to atezolizumab for the adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 1% [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 50% [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 10% TIIC [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + VEGF inhibition + Taxane-based chemotherapy + Platinum-based chemotherapy\nTherapy type: Immunotherapy + Targeted therapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to atezolizumab in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Atezolizumab + Paclitaxel + Carboplatin\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + Taxane-based chemotherapy + Platinum-based chemotherapy\nTherapy type: Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR somatic variants [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Atezolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Atezolizumab + Cobimetinib + Vemurafenib\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + MEK inhibition + B-RAF inhibition\nTherapy type: Immunotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600K [present]\nTherapy: Atezolizumab + Cobimetinib + Vemurafenib\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + MEK inhibition + B-RAF inhibition\nTherapy type: Immunotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\nPublication date: 2024-04-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.\nCancer type: Gastrointestinal Stromal Tumor\nBiomarkers: PDGFRA p.D842V [present]\nTherapy: Avapritinib\nTherapy approach: Monotherapy\nTherapy strategy: KIT inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Binimetinib + Encorafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf\nPublication date: 2023-10-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600K [present]\nTherapy: Binimetinib + Encorafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf\nPublication date: 2023-10-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: BRAF p.V600E [present]\nTherapy: Binimetinib + Encorafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf\nPublication date: 2023-10-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Letrozole\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: CD19 + [present]\nTherapy: Blinatumomab\nTherapy approach: Monotherapy\nTherapy strategy: CD19 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf\nPublication date: 2024-06-14",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: CD19 + [present]\nTherapy: Blinatumomab\nTherapy approach: Monotherapy\nTherapy strategy: CD19 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf\nPublication date: 2024-06-14",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: CD19 + [present], BCR::ABL1 [not present]\nTherapy: Blinatumomab\nTherapy approach: Monotherapy\nTherapy strategy: CD19 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf\nPublication date: 2024-06-14",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Bosutinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf\nPublication date: 2023-09-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Bosutinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf\nPublication date: 2023-09-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Bosutinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf\nPublication date: 2023-09-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.\nCancer type: Anaplastic Large Cell Lymphoma\nBiomarkers: CD30 + [present]\nTherapy: Brentuximab Vedotin + Cyclophosphamide + Doxorubicin + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: target CD30 antigens + Alkylating chemotherapy + Topoisomerase inhibition + Corticosteroid\nTherapy type: Targeted therapy + Chemotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf\nPublication date: 2023-06-14",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.\nCancer type: Anaplastic Large Cell Lymphoma\nBiomarkers: CD30 + [present]\nTherapy: Brentuximab Vedotin\nTherapy approach: Monotherapy\nTherapy strategy: target CD30 antigens\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf\nPublication date: 2023-06-14",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Brigatinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf\nPublication date: 2022-02-28",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capecitabine for the treatment of adult patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.\nCancer type: Adenocarcinoma of the Gastroesophageal Junction\nBiomarkers: HER2-positive [present]\nTherapy: Capecitabine\nTherapy approach: Monotherapy\nTherapy strategy: Thymidylate synthase inhibition\nTherapy type: Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf\nPublication date: 2022-12-14",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PIK3CA somatic variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], AKT1 somatic variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], AKT1 somatic variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], AKT1 somatic variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], AKT1 amplification [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], AKT1 amplification [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], AKT1 amplification [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PTEN nonsense variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], PTEN nonsense variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], PTEN nonsense variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PTEN frameshift variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], PTEN frameshift variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], PTEN frameshift variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PTEN splice site variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], PTEN splice site variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], PTEN splice site variants [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PTEN deletion [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], PTEN deletion [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], PTEN deletion [present]\nTherapy: Capivasertib + Fulvestrant\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Estrogen receptor inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: MET Exon 14 (Splice Site) [present]\nTherapy: Capmatinib\nTherapy approach: Monotherapy\nTherapy strategy: MET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf\nPublication date: 2024-03-14",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: MET Exon 14 (Deletion) [present]\nTherapy: Capmatinib\nTherapy approach: Monotherapy\nTherapy strategy: MET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf\nPublication date: 2024-03-14",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present], Wild type ROS1 [present]\nTherapy: Carboplatin + Cemiplimab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf\nPublication date: 2024-04-05",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to cemiplimab for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present], dMMR [present], PD-L1 >= 50% [present]\nTherapy: Cemiplimab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf\nPublication date: 2024-04-05",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ceritinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Ceritinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf\nPublication date: 2021-10-07",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to cetuximab in combination with FOLFIRI for the first-line treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer as determined by an FDA-approved test.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: EGFR positive [present], Wild type KRAS [present]\nTherapy: Cetuximab + Irinotecan + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + Topoisomerase I inhibition + Thymidylate synthase inhibition\nTherapy type: Targeted therapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf\nPublication date: 2021-09-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to cetuximab in combination with irinotecan for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: EGFR positive [present], Wild type KRAS [present]\nTherapy: Cetuximab + Irinotecan\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + Topoisomerase I inhibition\nTherapy type: Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf\nPublication date: 2021-09-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to cetuximab for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer, as determined by an FDA-approved test, who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: EGFR positive [present], Wild type KRAS [present]\nTherapy: Cetuximab\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf\nPublication date: 2021-09-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Encorafenib + Cetuximab\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + EGFR inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf\nPublication date: 2021-09-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Cobimetinib + Vemurafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf\nPublication date: 2023-05-31",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600K [present]\nTherapy: Cobimetinib + Vemurafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf\nPublication date: 2023-05-31",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Crizotinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition + MET inhibition + ROS1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf\nPublication date: 2023-09-07",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ROS1 [present]\nTherapy: Crizotinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition + MET inhibition + ROS1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf\nPublication date: 2023-09-07",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.\nCancer type: Anaplastic Large Cell Lymphoma\nBiomarkers: v::ALK [present]\nTherapy: Crizotinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition + MET inhibition + ROS1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf\nPublication date: 2023-09-07",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.\nCancer type: Inflammatory Myofibroblastic Tumor\nBiomarkers: v::ALK [present]\nTherapy: Crizotinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition + MET inhibition + ROS1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf\nPublication date: 2023-09-07",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib\nTherapy approach: Monotherapy\nTherapy strategy: B-RAF inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600K [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600K [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Abemaciclib + Letrozole\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.\nCancer type: Anaplastic Thyroid Cancer\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.\nCancer type: Any solid tumor\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.\nCancer type: Low-Grade Glioma, NOS\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Dacomitinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf\nPublication date: 2020-12-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Dacomitinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf\nPublication date: 2020-12-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Dasatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\nPublication date: 2023-02-08",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\nBiomarkers: BCR::ABL1 [present]\nTherapy: Dasatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\nPublication date: 2023-02-08",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Dasatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\nPublication date: 2023-02-08",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\nBiomarkers: BCR::ABL1 [present]\nTherapy: Dasatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\nPublication date: 2023-02-08",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Dasatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\nPublication date: 2023-02-08",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Dasatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\nPublication date: 2023-02-08",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\nBiomarkers: BCR::ABL1 [present]\nTherapy: Dasatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\nPublication date: 2023-02-08",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Dasatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf\nPublication date: 2023-02-08",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).\nCancer type: Endometrial Carcinoma\nBiomarkers: dMMR [present]\nTherapy: Carboplatin + Dostarlimab + Paclitaxel\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Taxane-based chemotherapy\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf\nPublication date: 2024-03-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).\nCancer type: Endometrial Carcinoma\nBiomarkers: MSI-H [present]\nTherapy: Carboplatin + Dostarlimab + Paclitaxel\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Taxane-based chemotherapy\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf\nPublication date: 2024-03-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.\nCancer type: Endometrial Carcinoma\nBiomarkers: dMMR [present]\nTherapy: Dostarlimab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf\nPublication date: 2024-03-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-Approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.\nCancer type: Any solid tumor\nBiomarkers: dMMR [present]\nTherapy: Dostarlimab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf\nPublication date: 2024-03-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Durvalumab + Tremelimumab + Pemetrexed + Carboplatin\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + CTLA-4 inhibition + Antifolate + Platinum-based chemotherapy\nTherapy type: Immunotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Durvalumab + Tremelimumab + Pemetrexed + Cisplatin\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + CTLA-4 inhibition + Antifolate + Platinum-based chemotherapy\nTherapy type: Immunotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Durvalumab + Tremelimumab + Gemcitabine + Carboplatin\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + CTLA-4 inhibition + Antimetabolite + Platinum-based chemotherapy\nTherapy type: Immunotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Durvalumab + Tremelimumab + Gemcitabine + Cisplatin\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + CTLA-4 inhibition + Antimetabolite + Platinum-based chemotherapy\nTherapy type: Immunotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Durvalumab + Tremelimumab + Nab-paclitaxel + Carboplatin\nTherapy approach: Combination therapy\nTherapy strategy: PD-1/PD-L1 inhibition + CTLA-4 inhibition + Taxane-based chemotherapy + Platinum-based chemotherapy\nTherapy type: Immunotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to durvalumab in combination with carboplatin and paclitaxel, followed by durvalumab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).\nCancer type: Endometrial Carcinoma\nBiomarkers: dMMR [present]\nTherapy: Carboplatin + Durvalumab + Paclitaxel\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Taxane-based chemotherapy\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to elacestrant for the treatment of patients who are postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], ESR1 oncogenic variants [present]\nTherapy: Elacestrant\nTherapy approach: Monotherapy\nTherapy strategy: ER signaling inhibition\nTherapy type: Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf\nPublication date: 2023-11-09",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH2 p.R140Q [present]\nTherapy: Enasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf\nPublication date: 2023-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH2 p.R140L [present]\nTherapy: Enasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf\nPublication date: 2023-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH2 p.R140G [present]\nTherapy: Enasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf\nPublication date: 2023-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH2 p.R140W [present]\nTherapy: Enasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf\nPublication date: 2023-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH2 p.R172K [present]\nTherapy: Enasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf\nPublication date: 2023-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH2 p.R172M [present]\nTherapy: Enasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf\nPublication date: 2023-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH2 p.R172G [present]\nTherapy: Enasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf\nPublication date: 2023-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH2 p.R172S [present]\nTherapy: Enasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf\nPublication date: 2023-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH2 p.R172W [present]\nTherapy: Enasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf\nPublication date: 2023-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Binimetinib + Encorafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf\nPublication date: 2024-12-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600K [present]\nTherapy: Binimetinib + Encorafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf\nPublication date: 2024-12-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Encorafenib + Cetuximab\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + EGFR inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf\nPublication date: 2024-12-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: BRAF p.V600E [present]\nTherapy: Binimetinib + Encorafenib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + B-RAF inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf\nPublication date: 2024-12-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to entrectinib for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ROS1 [present]\nTherapy: Entrectinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition + ROS1 inhibition + NTRK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf\nPublication date: 2024-01-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.\nCancer type: Any solid tumor\nBiomarkers: v::NTRK1 [present]\nTherapy: Entrectinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition + ROS1 inhibition + NTRK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf\nPublication date: 2024-01-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.\nCancer type: Any solid tumor\nBiomarkers: v::NTRK2 [present]\nTherapy: Entrectinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition + ROS1 inhibition + NTRK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf\nPublication date: 2024-01-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.\nCancer type: Any solid tumor\nBiomarkers: v::NTRK3 [present]\nTherapy: Entrectinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition + ROS1 inhibition + NTRK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf\nPublication date: 2024-01-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.\nCancer type: Bladder Urothelial Carcinoma\nBiomarkers: FGFR3 p.R248C [present]\nTherapy: Erdafitinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\nPublication date: 2024-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.\nCancer type: Bladder Urothelial Carcinoma\nBiomarkers: FGFR3 p.S249C [present]\nTherapy: Erdafitinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\nPublication date: 2024-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.\nCancer type: Bladder Urothelial Carcinoma\nBiomarkers: FGFR3 p.G370C [present]\nTherapy: Erdafitinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\nPublication date: 2024-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.\nCancer type: Bladder Urothelial Carcinoma\nBiomarkers: FGFR3 p.Y373C [present]\nTherapy: Erdafitinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\nPublication date: 2024-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.\nCancer type: Bladder Urothelial Carcinoma\nBiomarkers: FGFR3::TACC3 [present]\nTherapy: Erdafitinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf\nPublication date: 2024-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Erlotinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf\nPublication date: 2016-10-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Erlotinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf\nPublication date: 2016-10-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Everolimus + Exemestane\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf\nPublication date: 2022-02-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Everolimus + Exemestane\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf\nPublication date: 2022-02-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Everolimus + Exemestane\nTherapy approach: Combination therapy\nTherapy strategy: PI3K/AKT/mTOR inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf\nPublication date: 2022-02-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Fulvestrant\nTherapy approach: Monotherapy\nTherapy strategy: Estrogen receptor inhibition\nTherapy type: Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant\nTherapy approach: Monotherapy\nTherapy strategy: Estrogen receptor inhibition\nTherapy type: Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant\nTherapy approach: Monotherapy\nTherapy strategy: Estrogen receptor inhibition\nTherapy type: Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present]\nTherapy: Fulvestrant\nTherapy approach: Monotherapy\nTherapy strategy: Estrogen receptor inhibition\nTherapy type: Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: PR positive [present]\nTherapy: Fulvestrant\nTherapy approach: Monotherapy\nTherapy strategy: Estrogen receptor inhibition\nTherapy type: Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], PR positive [present]\nTherapy: Fulvestrant\nTherapy approach: Monotherapy\nTherapy strategy: Estrogen receptor inhibition\nTherapy type: Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Fulvestrant + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Fulvestrant + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Fulvestrant + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Abemaciclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf\nPublication date: 2021-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. Futibatinib's package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Intrahepatic Cholangiocarcinoma\nBiomarkers: FGFR2::v [present]\nTherapy: Futibatinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214801s002lbl.pdf\nPublication date: 2024-04-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Gefitinib's package insert includes the following limitation of use: safety and efficacy of gefitinib have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Gefitinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf\nPublication date: 2021-05-05",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Gefitinib's package insert includes the following limitation of use: safety and efficacy of gefitinib have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Gefitinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf\nPublication date: 2021-05-05",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 1 month or older with newly-diagnosed CD33-positive acute myeloid leukemia (AML).\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: CD33 + [present]\nTherapy: Gemtuzumab ozogamicin\nTherapy approach: Monotherapy\nTherapy strategy: CD33 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf\nPublication date: 2020-06-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 1 month or older with newly-diagnosed CD33-positive acute myeloid leukemia (AML).\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: CD33 + [present]\nTherapy: Gemtuzumab ozogamicin\nTherapy approach: Monotherapy\nTherapy strategy: CD33 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf\nPublication date: 2020-06-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: FLT3-ITD [present]\nTherapy: Gilteritinib\nTherapy approach: Monotherapy\nTherapy strategy: FLT3 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf\nPublication date: 2022-01-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: FLT3 p.D835Y [present]\nTherapy: Gilteritinib\nTherapy approach: Monotherapy\nTherapy strategy: FLT3 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf\nPublication date: 2022-01-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: FLT3 p.D835A [present]\nTherapy: Gilteritinib\nTherapy approach: Monotherapy\nTherapy strategy: FLT3 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf\nPublication date: 2022-01-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: FLT3 p.D835E [present]\nTherapy: Gilteritinib\nTherapy approach: Monotherapy\nTherapy strategy: FLT3 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf\nPublication date: 2022-01-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: FLT3 p.D835H [present]\nTherapy: Gilteritinib\nTherapy approach: Monotherapy\nTherapy strategy: FLT3 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf\nPublication date: 2022-01-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: FLT3 p.D835N [present]\nTherapy: Gilteritinib\nTherapy approach: Monotherapy\nTherapy strategy: FLT3 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf\nPublication date: 2022-01-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: FLT3 p.D835S [present]\nTherapy: Gilteritinib\nTherapy approach: Monotherapy\nTherapy strategy: FLT3 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf\nPublication date: 2022-01-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: FLT3 p.D835V [present]\nTherapy: Gilteritinib\nTherapy approach: Monotherapy\nTherapy strategy: FLT3 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf\nPublication date: 2022-01-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\nBiomarkers: BCR::ABL1 [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\nBiomarkers: BCR::ABL1 [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.\nCancer type: Myelodysplastic Syndromes\nBiomarkers: PDGFRA rearrangements [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.\nCancer type: Myelodysplastic Syndromes\nBiomarkers: PDGFRB rearrangements [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.\nCancer type: Aggressive Systemic Mastocytosis\nBiomarkers: KIT p.D816V [not present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.\nCancer type: Chronic Eosinophilic Leukemia, NOS\nBiomarkers: FIP1L1::PDGFRA [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).\nCancer type: Gastrointestinal Stromal Tumor\nBiomarkers: CD117 + [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to imatinib for the adjuvant treatment of adult patients following resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST).\nCancer type: Gastrointestinal Stromal Tumor\nBiomarkers: FIP1L1::PDGFRA [present]\nTherapy: Imatinib\nTherapy approach: Monotherapy\nTherapy strategy: Bcr-Abl inhibition + c-Kit inhibition + PDGF-R inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\nPublication date: 2024-03-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to infigratinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).\nCancer type: Cholangiocarcinoma\nBiomarkers: FGFR2::v [present]\nTherapy: Infigratinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf\nPublication date: 2021-05-28",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to inotuzumab ozogamicin for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: CD22 + [present]\nTherapy: Inotuzumab ozogamicin\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf\nPublication date: 2024-03-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: MSI-H [present]\nTherapy: Ipilimumab + Nivolumab\nTherapy approach: Combination therapy\nTherapy strategy: CTLA-4 inhibition + PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: dMMR [present]\nTherapy: Ipilimumab + Nivolumab\nTherapy approach: Combination therapy\nTherapy strategy: CTLA-4 inhibition + PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>=1%), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 1% [present], Wild type ALK [present], Wild type EGFR [present]\nTherapy: Ipilimumab + Nivolumab\nTherapy approach: Combination therapy\nTherapy strategy: CTLA-4 inhibition + PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Ipilimumab + Nivolumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + CTLA-4 inhibition + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Cisplatin + Ipilimumab + Nivolumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + CTLA-4 inhibition + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Ipilimumab + Nivolumab + Paclitaxel\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + CTLA-4 inhibition + PD-1/PD-L1 inhibition + Taxane-based chemotherapy\nTherapy type: Chemotherapy + Immunotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132C [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132G [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132H [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132L [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132S [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132C [present]\nTherapy: Azacitidine + Ivosidenib\nTherapy approach: Combination therapy\nTherapy strategy: Hypomethylating agent chemotherapy + IDH1 inhibition\nTherapy type: Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132G [present]\nTherapy: Azacitidine + Ivosidenib\nTherapy approach: Combination therapy\nTherapy strategy: Hypomethylating agent chemotherapy + IDH1 inhibition\nTherapy type: Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132H [present]\nTherapy: Azacitidine + Ivosidenib\nTherapy approach: Combination therapy\nTherapy strategy: Hypomethylating agent chemotherapy + IDH1 inhibition\nTherapy type: Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132L [present]\nTherapy: Azacitidine + Ivosidenib\nTherapy approach: Combination therapy\nTherapy strategy: Hypomethylating agent chemotherapy + IDH1 inhibition\nTherapy type: Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132S [present]\nTherapy: Azacitidine + Ivosidenib\nTherapy approach: Combination therapy\nTherapy strategy: Hypomethylating agent chemotherapy + IDH1 inhibition\nTherapy type: Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132C [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132G [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132H [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132L [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132S [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Myelodysplastic Syndromes\nBiomarkers: IDH1 p.R132C [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Myelodysplastic Syndromes\nBiomarkers: IDH1 p.R132G [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Myelodysplastic Syndromes\nBiomarkers: IDH1 p.R132H [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Myelodysplastic Syndromes\nBiomarkers: IDH1 p.R132L [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Myelodysplastic Syndromes\nBiomarkers: IDH1 p.R132S [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).\nCancer type: Cholangiocarcinoma\nBiomarkers: IDH1 p.R132C [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).\nCancer type: Cholangiocarcinoma\nBiomarkers: IDH1 p.R132G [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).\nCancer type: Cholangiocarcinoma\nBiomarkers: IDH1 p.R132H [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).\nCancer type: Cholangiocarcinoma\nBiomarkers: IDH1 p.R132L [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).\nCancer type: Cholangiocarcinoma\nBiomarkers: IDH1 p.R132S [present]\nTherapy: Ivosidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\nPublication date: 2023-10-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to lapatinib in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, a trastuzumab.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Capecitabine + Lapatinib\nTherapy approach: Combination therapy\nTherapy strategy: Thymidylate synthase inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf\nPublication date: 2022-03-27",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-positive [present]\nTherapy: Lapatinib + Letrozole\nTherapy approach: Combination therapy\nTherapy strategy: HER2 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf\nPublication date: 2022-03-27",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: PR positive [present], HER2-positive [present]\nTherapy: Lapatinib + Letrozole\nTherapy approach: Combination therapy\nTherapy strategy: HER2 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf\nPublication date: 2022-03-27",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], PR positive [present], HER2-positive [present]\nTherapy: Lapatinib + Letrozole\nTherapy approach: Combination therapy\nTherapy strategy: HER2 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf\nPublication date: 2022-03-27",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.\nCancer type: Any solid tumor\nBiomarkers: v::NTRK1 [present]\nTherapy: Larotrectinib\nTherapy approach: Monotherapy\nTherapy strategy: NTRK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf\nPublication date: 2025-04-09",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.\nCancer type: Any solid tumor\nBiomarkers: v::NTRK2 [present]\nTherapy: Larotrectinib\nTherapy approach: Monotherapy\nTherapy strategy: NTRK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf\nPublication date: 2025-04-09",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.\nCancer type: Any solid tumor\nBiomarkers: v::NTRK3 [present]\nTherapy: Larotrectinib\nTherapy approach: Monotherapy\nTherapy strategy: NTRK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf\nPublication date: 2025-04-09",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to lenalidomide for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.\nCancer type: Myelodysplastic Syndromes\nBiomarkers: 5q deletion [present]\nTherapy: Lenalidomide\nTherapy approach: Monotherapy\nTherapy strategy: Angiogenesis inhibition\nTherapy type: Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf\nPublication date: 2023-03-24",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to lorlatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Lorlatinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf\nPublication date: 2021-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Capecitabine + Margetuximab\nTherapy approach: Combination therapy\nTherapy strategy: Thymidylate synthase inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf\nPublication date: 2023-05-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Eribulin + Margetuximab\nTherapy approach: Combination therapy\nTherapy strategy: Tubulin polymerization inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf\nPublication date: 2023-05-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Gemcitabine + Margetuximab\nTherapy approach: Combination therapy\nTherapy strategy: Antimetabolite + HER2 inhibition\nTherapy type: Chemotherapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf\nPublication date: 2023-05-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Margetuximab + Vinorelbine\nTherapy approach: Combination therapy\nTherapy strategy: HER2 inhibition + Vinca alkaloid chemotherapy\nTherapy type: Hormone therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf\nPublication date: 2023-05-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: FLT3-ITD [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: FLT3 p.D835Y [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: FLT3 p.D835A [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: FLT3 p.D835E [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: FLT3 p.D835H [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: FLT3 p.D835N [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: FLT3 p.D835S [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: FLT3 p.D835V [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: FLT3 p.I836del [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: CDK12 oncogenic variants [present]\nTherapy: Cytarabine + Daunorubicin + Midostaurin\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + DNA Polymerase inhibition + FLT3 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf\nPublication date: 2023-05-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 20 (Insertion) [present]\nTherapy: Mobocertinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf\nPublication date: 2023-09-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to neratinib for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Neratinib\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf\nPublication date: 2021-06-28",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Capecitabine + Neratinib\nTherapy approach: Combination therapy\nTherapy strategy: Thymidylate synthase inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf\nPublication date: 2021-06-28",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Nilotinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf\nPublication date: 2024-02-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\nBiomarkers: BCR::ABL1 [present]\nTherapy: Nilotinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf\nPublication date: 2024-02-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Nilotinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf\nPublication date: 2024-02-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\nBiomarkers: BCR::ABL1 [present]\nTherapy: Nilotinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf\nPublication date: 2024-02-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Niraparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf\nPublication date: 2023-04-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Niraparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf\nPublication date: 2023-04-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Niraparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf\nPublication date: 2023-04-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Niraparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf\nPublication date: 2023-04-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Niraparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf\nPublication date: 2023-04-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Niraparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf\nPublication date: 2023-04-26",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Nivolumab + Paclitaxel\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Taxane-based chemotherapy\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>= 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 1% [present]\nTherapy: Ipilimumab + Nivolumab\nTherapy approach: Combination therapy\nTherapy strategy: CTLA-4 inhibition + PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: HRD [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: HRD [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: HRD [present]\nTherapy: Bevacizumab + Olaparib\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + PARP inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: BRCA1 pathogenic variants [present], HER2-negative [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: BRCA2 pathogenic variants [present], HER2-negative [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: BRCA1 pathogenic variants [present], HER2-negative [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: BRCA2 pathogenic variants [present], HER2-negative [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Pancreatic Adenocarcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Pancreatic Adenocarcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: ATM pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: ATM oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BARD1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BARD1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRIP1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRIP1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CDK12 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CDK12 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CHEK1 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CHEK1 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CHEK2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CHEK2 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: FANCL pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: FANCL oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: PALB2 pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: PALB2 oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD51B pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD51B oncogenic variants [present]\nTherapy: Talazoparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD51C pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD51C oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD51D pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD51D oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD54L pathogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD54L oncogenic variants [present]\nTherapy: Olaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Abiraterone acetate + Olaparib + Prednisolone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Abiraterone acetate + Olaparib + Prednisolone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Abiraterone acetate + Olaparib + Prednisolone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Abiraterone acetate + Olaparib + Prednisolone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Abiraterone acetate + Olaparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Abiraterone acetate + Olaparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Abiraterone acetate + Olaparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Abiraterone acetate + Olaparib + Prednisone\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition + Corticosteroid\nTherapy type: Hormone therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\nPublication date: 2023-11-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132C [present]\nTherapy: Olutasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf\nPublication date: 2022-12-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132G [present]\nTherapy: Olutasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf\nPublication date: 2022-12-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132H [present]\nTherapy: Olutasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf\nPublication date: 2022-12-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132L [present]\nTherapy: Olutasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf\nPublication date: 2022-12-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: IDH1 p.R132S [present]\nTherapy: Olutasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf\nPublication date: 2022-12-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Osimertinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Osimertinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Osimertinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Osimertinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Cisplatin + Osimertinib + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + EGFR inhibition + Antifolate\nTherapy type: Chemotherapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Carboplatin + Osimertinib + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + EGFR inhibition + Antifolate\nTherapy type: Chemotherapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Carboplatin + Osimertinib + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + EGFR inhibition + Antifolate\nTherapy type: Chemotherapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Cisplatin + Osimertinib + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + EGFR inhibition + Antifolate\nTherapy type: Chemotherapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.T790M [present]\nTherapy: Osimertinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Letrozole + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf\nPublication date: 2023-09-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Letrozole + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf\nPublication date: 2023-09-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Letrozole + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf\nPublication date: 2023-09-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Fulvestrant + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf\nPublication date: 2023-09-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf\nPublication date: 2023-09-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf\nPublication date: 2023-09-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to panitumumab in combination with FOLFOX for the first-line treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS, as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC). The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: Wild type KRAS [present], Wild type HRAS [present]\nTherapy: Oxaliplatin + Panitumumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + EGFR inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf\nPublication date: 2021-08-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to panitumumab for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC)following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: Wild type KRAS [present], Wild type HRAS [present]\nTherapy: Panitumumab\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf\nPublication date: 2021-08-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Pembrolizumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Cisplatin + Pembrolizumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with non-small cell lung cancer expressing PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 1% [present], Wild type ALK [present], Wild type EGFR [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with disease progression on or after platinum containing chemotherapy. The product label further states that patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: PD-L1 >= 1% [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) >=1] as determined by an FDA-approved test.\nCancer type: Head and Neck Squamous Cell Carcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.\nCancer type: Any solid tumor\nBiomarkers: dMMR [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.\nCancer type: Any solid tumor\nBiomarkers: MSI-H [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), as determined by an FDA-approved test.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: dMMR [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), as determined by an FDA-approved test.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: MSI-H [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on tumor response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. This indication is based on KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of chemotherapy between either cisplatin and 5-fu, or oxaliplatin and capecitabine.\nCancer type: Adenocarcinoma of the Gastroesophageal Junction\nBiomarkers: HER2-positive [present], PD-L1 (CPS) >= 1 [present]\nTherapy: Cisplatin + Pembrolizumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Immunotherapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on tumor response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. This indication is based on KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of chemotherapy between either cisplatin and 5-fu, or oxaliplatin and capecitabine.\nCancer type: Adenocarcinoma of the Gastroesophageal Junction\nBiomarkers: HER2-positive [present], PD-L1 (CPS) >= 1 [present]\nTherapy: Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Thymidylate synthase inhibition + Platinum-based chemotherapy + PD-1/PD-L1 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.\nCancer type: Adenocarcinoma of the Gastroesophageal Junction\nBiomarkers: HER2-negative [present]\nTherapy: Cisplatin + Pembrolizumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.\nCancer type: Adenocarcinoma of the Gastroesophageal Junction\nBiomarkers: HER2-negative [present]\nTherapy: Capecitabine + Oxaliplatin + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: Thymidylate synthase inhibition + Platinum-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.\nCancer type: Adenocarcinoma of the Gastroesophageal Junction\nBiomarkers: PD-L1 (CPS) >= 10 [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.\nCancer type: Esophageal Adenocarcinoma\nBiomarkers: PD-L1 (CPS) >= 10 [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.\nCancer type: Cervical Adenocarcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Cisplatin + Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.\nCancer type: Cervical Squamous Cell Carcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Cisplatin + Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.\nCancer type: Cervical Adenocarcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + Platinum-based chemotherapy + Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Targeted therapy + Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.\nCancer type: Cervical Squamous Cell Carcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + Platinum-based chemotherapy + Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Targeted therapy + Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.\nCancer type: Cervical Adenocarcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Carboplatin + Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.\nCancer type: Cervical Squamous Cell Carcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Carboplatin + Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.\nCancer type: Cervical Adenocarcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + Platinum-based chemotherapy + Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Targeted therapy + Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.\nCancer type: Cervical Squamous Cell Carcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: VEGF inhibition + Platinum-based chemotherapy + Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Targeted therapy + Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.\nCancer type: Cervical Adenocarcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.\nCancer type: Cervical Squamous Cell Carcinoma\nBiomarkers: PD-L1 (CPS) >= 1 [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with lenvatinib for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.\nCancer type: Endometrial Carcinoma\nBiomarkers: MSI-L [present]\nTherapy: Lenvatinib + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: VEGFR inhibition + PD-1/PD-L1 inhibition\nTherapy type: Targeted therapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is mismatch repair deficient (MMRd) or microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.\nCancer type: Endometrial Carcinoma\nBiomarkers: pMMR [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is mismatch repair deficient (MMRd) or microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.\nCancer type: Endometrial Carcinoma\nBiomarkers: MSI-H [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The product label states that the safety and effectiveness of pembrolizumab in pediatric patients with TMB-H central nervous system cancers have not been established and that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, it states that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.\nCancer type: Any solid tumor\nBiomarkers: TMB-H (>= 10 mutations / Mb) [present]\nTherapy: Pembrolizumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then pembrolizumab continued as a single agent as adjuvant treatment after surgery, of patients with high-risk early-stage triple negative breast cancer (TNBC). This indication is based on KEYNOTE-522 (NCT03036488), a randomized (2:1), multicenter, double-blind, placebo-controlled trial where the chemotherapy regimen consisted of carboplatin, paclitaxel, doxorubicin, and cyclophosphamide.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER negative [present], HER2-negative [present], PR negative [present]\nTherapy: Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: PD-L1 (CPS) >= 10 [present], ER negative [present], HER2-negative [present], PR negative [present]\nTherapy: Paclitaxel + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: Taxane-based chemotherapy + PD-1/PD-L1 inhibition\nTherapy type: Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: PD-L1 (CPS) >= 10 [present], ER negative [present], HER2-negative [present], PR negative [present]\nTherapy: Carboplatin + Gemcitabine + Pembrolizumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Antimetabolite + PD-1/PD-L1 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\nPublication date: 2025-04-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Cholangiocarcinoma\nBiomarkers: FGFR2::v [present]\nTherapy: Pemigatinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf\nPublication date: 2020-04-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Cholangiocarcinoma\nBiomarkers: FGFR2 rearrangements [present]\nTherapy: Pemigatinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf\nPublication date: 2020-04-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pemigatinib for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.\nCancer type: Myeloid/Lymphoid Neoplasms\nBiomarkers: FGFR1 rearrangements [present]\nTherapy: Pemigatinib\nTherapy approach: Monotherapy\nTherapy strategy: FGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf\nPublication date: 2020-04-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Docetaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Epirubicin + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Docetaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Epirubicin + Paclitaxel + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Doxorubicin + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Epirubicin + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Epirubicin + Paclitaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Doxorubicin + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Epirubicin + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Carboplatin + Docetaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Epirubicin + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Carboplatin + Docetaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Epirubicin + Paclitaxel + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Doxorubicin + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Epirubicin + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Epirubicin + Paclitaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Doxorubicin + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\nPublication date: 2020-06-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + Taxane-based chemotherapy + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Cyclophosphamide + Docetaxel + Epirubicin + Pertuzumab + Trastuzumab + Fluorouracil\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Taxane-based chemotherapy + Topoisomerase inhibition + HER2 inhibition + HER2 inhibition + Thymidylate synthase inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\nPublication date: 2020-01-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The product label notes that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). This indication is based on PhALLCON (NCT03589326), a randomized, active-controlled, multicenter, open-label trial in which chemotherapy regimens were: vincristine and dexamethasone (induction, cycles 1 to 3); methotrexate and cytarabine (consolidation, cycles 4 to 9, alternating methotrexate and cytarabine); and vincristine and prednisone (maintenance, cycles 10 to 20).\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Cytarabine + Methotrexate + Ponatinib + Prednisone + Vincristine\nTherapy approach: Combination therapy\nTherapy strategy: DNA Polymerase inhibition + Antifolate + BCR-ABL inhibition + Corticosteroid + Vinca alkaloid chemotherapy\nTherapy type: Chemotherapy + Chemotherapy + Targeted therapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf\nPublication date: 2024-03-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: ABL1 p.T315I [present], BCR::ABL1 [present]\nTherapy: Ponatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf\nPublication date: 2024-03-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast phase. The product label states the following limitations of use: ponatinib is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: ABL1 p.T315I [present]\nTherapy: Ponatinib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf\nPublication date: 2024-03-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to pralsetinib for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as detected by an FDA approved test (NSCLC).\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::RET [present]\nTherapy: Pralsetinib\nTherapy approach: Monotherapy\nTherapy strategy: RET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf\nPublication date: 2024-03-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). This indication is based on ARROW (NCT03037385), a multicenter, open-label, multi-cohort clinical trial where all enrolled patients had papillary thyroid cancer.\nCancer type: Papillary Thyroid Cancer\nBiomarkers: v::RET [present]\nTherapy: Pralsetinib\nTherapy approach: Monotherapy\nTherapy strategy: RET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf\nPublication date: 2024-03-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Erlotinib + Ramucirumab\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + VEGF/VEGFR inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf\nPublication date: 2022-03-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Erlotinib + Ramucirumab\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + VEGF/VEGFR inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf\nPublication date: 2022-03-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ROS1 [present]\nTherapy: Repotrectinib\nTherapy approach: Monotherapy\nTherapy strategy: ROS inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf\nPublication date: 2024-06-13",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\nCancer type: Any solid tumor\nBiomarkers: v::NTRK1 [present]\nTherapy: Repotrectinib\nTherapy approach: Monotherapy\nTherapy strategy: ROS inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf\nPublication date: 2024-06-13",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\nCancer type: Any solid tumor\nBiomarkers: v::NTRK2 [present]\nTherapy: Repotrectinib\nTherapy approach: Monotherapy\nTherapy strategy: ROS inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf\nPublication date: 2024-06-13",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\nCancer type: Any solid tumor\nBiomarkers: v::NTRK3 [present]\nTherapy: Repotrectinib\nTherapy approach: Monotherapy\nTherapy strategy: ROS inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf\nPublication date: 2024-06-13",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Anastrozole + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Anastrozole + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Anastrozole + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Letrozole + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Letrozole + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Letrozole + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Fulvestrant + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Fulvestrant + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL).\nCancer type: Non-Hodgkin Lymphoma\nBiomarkers: CD20 + [present]\nTherapy: Rituximab\nTherapy approach: Monotherapy\nTherapy strategy: CD20 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).\nCancer type: Non-Hodgkin Lymphoma\nBiomarkers: CD20 + [present]\nTherapy: Cyclophosphamide + Rituximab + Prednisolone + Vincristine\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + CD20 inhibition + Corticosteroid + Vinca alkaloid chemotherapy\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).\nCancer type: Non-Hodgkin Lymphoma\nBiomarkers: CD20 + [present]\nTherapy: Cyclophosphamide + Doxorubicin + Rituximab + Prednisolone + Vincristine\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + CD20 inhibition + Corticosteroid + Vinca alkaloid chemotherapy\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).\nCancer type: Non-Hodgkin Lymphoma\nBiomarkers: CD20 + [present]\nTherapy: Cyclophosphamide + Fludarabine + Mitoxantrone + Rituximab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Antimetabolite + Topoisomerase inhibition + CD20 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL).\nCancer type: Non-Hodgkin Lymphoma\nBiomarkers: CD20 + [present]\nTherapy: Rituximab\nTherapy approach: Monotherapy\nTherapy strategy: CD20 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive Non-Hodgkin's Lymphoma (NHL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrolled of 1854 patients. The product label did not specify the name of the clinical trial name (Study 9) that administered an anthracycline-containing chemotherapy regimen, or what the specific regimen was.\nCancer type: Non-Hodgkin Lymphoma\nBiomarkers: CD20 + [present]\nTherapy: Cyclophosphamide + Doxorubicin + Rituximab + Prednisone + Vincristine\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + CD20 inhibition + Corticosteroid + Vinca alkaloid chemotherapy\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive Non-Hodgkin's Lymphoma (NHL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrolled of 1854 patients. The product label did not specify the name of the clinical trial name (Study 9) that administered an anthracycline-containing chemotherapy regimen, or what the specific regimen was.\nCancer type: Non-Hodgkin Lymphoma\nBiomarkers: CD20 + [present]\nTherapy: Cyclophosphamide + Doxorubicin + Rituximab + Prednisone + Vincristine\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + CD20 inhibition + Corticosteroid + Vinca alkaloid chemotherapy\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.\nCancer type: Diffuse Large B-Cell Lymphoma\nBiomarkers: CD20 + [present]\nTherapy: Cyclophosphamide + Doxorubicin + Rituximab + Prednisone + Vincristine\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + CD20 inhibition + Corticosteroid + Vinca alkaloid chemotherapy\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.\nCancer type: Burkitt Lymphoma\nBiomarkers: CD20 + [present]\nTherapy: Cyclophosphamide + Doxorubicin + Rituximab + Prednisone + Vincristine\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + CD20 inhibition + Corticosteroid + Vinca alkaloid chemotherapy\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.\nCancer type: Mature B-Cell Neoplasms\nBiomarkers: CD20 + [present]\nTherapy: Cyclophosphamide + Doxorubicin + Rituximab + Prednisone + Vincristine\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Topoisomerase inhibition + CD20 inhibition + Corticosteroid + Vinca alkaloid chemotherapy\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rituximab in combination with fludarabine and cyclophosphamide for the treatment of previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL).\nCancer type: Chronic Lymphocytic Leukemia\nBiomarkers: CD20 + [present]\nTherapy: Cyclophosphamide + Fludarabine + Rituximab\nTherapy approach: Combination therapy\nTherapy strategy: Alkylating chemotherapy + Antimetabolite + CD20 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf\nPublication date: 2021-12-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 oncogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Rucaparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf\nPublication date: 2022-12-21",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER negative [present], HER2-negative [present], PR negative [present]\nTherapy: Sacituzumab govitecan\nTherapy approach: Monotherapy\nTherapy strategy: Topoisomerase inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf\nPublication date: 2023-02-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Sacituzumab govitecan\nTherapy approach: Monotherapy\nTherapy strategy: Topoisomerase inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf\nPublication date: 2023-02-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Sacituzumab govitecan\nTherapy approach: Monotherapy\nTherapy strategy: Topoisomerase inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf\nPublication date: 2023-02-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Sacituzumab govitecan\nTherapy approach: Monotherapy\nTherapy strategy: Topoisomerase inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf\nPublication date: 2023-02-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::RET [present]\nTherapy: Selpercatinib\nTherapy approach: Monotherapy\nTherapy strategy: RET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf\nPublication date: 2024-09-27",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.\nCancer type: Medullary Thyroid Cancer\nBiomarkers: RET oncogenic variants [present]\nTherapy: Selpercatinib\nTherapy approach: Monotherapy\nTherapy strategy: RET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf\nPublication date: 2024-09-27",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).\nCancer type: Anaplastic Thyroid Cancer\nBiomarkers: v::RET [present]\nTherapy: Selpercatinib\nTherapy approach: Monotherapy\nTherapy strategy: RET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf\nPublication date: 2024-09-27",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).\nCancer type: Any solid tumor\nBiomarkers: v::RET [present]\nTherapy: Selpercatinib\nTherapy approach: Monotherapy\nTherapy strategy: RET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf\nPublication date: 2024-09-27",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. The product label states that this indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: KRAS p.G12C [present]\nTherapy: Sotorasib\nTherapy approach: Monotherapy\nTherapy strategy: RAS inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf\nPublication date: 2023-04-23",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: BRCA1 pathogenic variants [present], HER2-negative [present]\nTherapy: Talazoparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: BRCA2 pathogenic variants [present], HER2-negative [present]\nTherapy: Talazoparib\nTherapy approach: Monotherapy\nTherapy strategy: PARP inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: MET Exon 14 (Splice Site) [present]\nTherapy: Tepotinib\nTherapy approach: Monotherapy\nTherapy strategy: MET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf\nPublication date: 2024-02-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: MET Exon 14 (Deletion) [present]\nTherapy: Tepotinib\nTherapy approach: Monotherapy\nTherapy strategy: MET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf\nPublication date: 2024-02-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Trametinib\nTherapy approach: Monotherapy\nTherapy strategy: MEK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600K [present]\nTherapy: Trametinib\nTherapy approach: Monotherapy\nTherapy strategy: MEK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.\nCancer type: Anaplastic Thyroid Cancer\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.\nCancer type: Any solid tumor\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.\nCancer type: Low-Grade Glioma, NOS\nBiomarkers: BRAF p.V600E [present]\nTherapy: Dabrafenib + Trametinib\nTherapy approach: Combination therapy\nTherapy strategy: B-RAF inhibition + MEK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf\nPublication date: 2024-03-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer. The product label specifies to select  patients for therapy based on an FDA-approved companion diagnostic for herceptin.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Trastuzumab\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf\nPublication date: 2024-06-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab.\nCancer type: Gastrointestinal Stromal Tumor\nBiomarkers: HER2-positive [present]\nTherapy: Trastuzumab\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf\nPublication date: 2024-06-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Trastuzumab deruxtecan\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf\nPublication date: 2024-04-05",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-low [present]\nTherapy: Trastuzumab deruxtecan\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf\nPublication date: 2024-04-05",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. The product label states that these indications are approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: ERBB2 oncogenic variants [present]\nTherapy: Trastuzumab deruxtecan\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf\nPublication date: 2024-04-05",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.\nCancer type: Adenocarcinoma of the Gastroesophageal Junction\nBiomarkers: HER2-positive [present]\nTherapy: Trastuzumab deruxtecan\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf\nPublication date: 2024-04-05",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.\nCancer type: Any solid tumor\nBiomarkers: HER2-positive [present]\nTherapy: Trastuzumab deruxtecan\nTherapy approach: Monotherapy\nTherapy strategy: HER2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf\nPublication date: 2024-04-05",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Capecitabine + Trastuzumab + Tucatinib\nTherapy approach: Combination therapy\nTherapy strategy: Thymidylate synthase inhibition + HER2 inhibition + HER2 inhibition\nTherapy type: Chemotherapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf\nPublication date: 2023-01-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.\nCancer type: Melanoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Vemurafenib\nTherapy approach: Monotherapy\nTherapy strategy: B-RAF inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf\nPublication date: 2020-05-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.\nCancer type: Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease\nBiomarkers: BRAF p.V600E [present]\nTherapy: Vemurafenib\nTherapy approach: Monotherapy\nTherapy strategy: B-RAF inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf\nPublication date: 2020-05-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.\nCancer type: Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease\nBiomarkers: BRAF p.V600K [present]\nTherapy: Vemurafenib\nTherapy approach: Monotherapy\nTherapy strategy: B-RAF inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf\nPublication date: 2020-05-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Follicular Lymphoma\nBiomarkers: EZH2 p.Y646N [present]\nTherapy: Tazemetostat\nTherapy approach: Monotherapy\nTherapy strategy: EZH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Follicular Lymphoma\nBiomarkers: EZH2 p.Y646F [present]\nTherapy: Tazemetostat\nTherapy approach: Monotherapy\nTherapy strategy: EZH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Follicular Lymphoma\nBiomarkers: EZH2 p.Y646H [present]\nTherapy: Tazemetostat\nTherapy approach: Monotherapy\nTherapy strategy: EZH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Follicular Lymphoma\nBiomarkers: EZH2 p.Y646S [present]\nTherapy: Tazemetostat\nTherapy approach: Monotherapy\nTherapy strategy: EZH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Follicular Lymphoma\nBiomarkers: EZH2 p.Y646C [present]\nTherapy: Tazemetostat\nTherapy approach: Monotherapy\nTherapy strategy: EZH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Follicular Lymphoma\nBiomarkers: EZH2 p.A862G [present]\nTherapy: Tazemetostat\nTherapy approach: Monotherapy\nTherapy strategy: EZH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Follicular Lymphoma\nBiomarkers: EZH2 p.A692V [present]\nTherapy: Tazemetostat\nTherapy approach: Monotherapy\nTherapy strategy: EZH2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf\nPublication date: 2023-11-16",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA1 pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: BRCA2 pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: ATM pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: ATM oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: ATR oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CDK12 oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: ATR pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: FANCA oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CHEK2 pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CHEK2 oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: FANCA pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: MLH1 oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: PALB2 pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: PALB2 oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: MLH1 pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: MRE11 oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD51C pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: RAD51C oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: MRE11 pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: NBN oncogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: NBN pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.\nCancer type: Renal Angiomyolipoma\nBiomarkers: TSC1 oncogenic variants [present]\nTherapy: Everolimus\nTherapy approach: Monotherapy\nTherapy strategy: PI3K/AKT/mTOR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf\nPublication date: 2022-02-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.\nCancer type: Renal Angiomyolipoma\nBiomarkers: TSC2 oncogenic variants [present]\nTherapy: Everolimus\nTherapy approach: Monotherapy\nTherapy strategy: PI3K/AKT/mTOR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf\nPublication date: 2022-02-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.\nCancer type: Anaplastic Thyroid Cancer\nBiomarkers: TSC1 oncogenic variants [present]\nTherapy: Everolimus\nTherapy approach: Monotherapy\nTherapy strategy: PI3K/AKT/mTOR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf\nPublication date: 2022-02-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.\nCancer type: Anaplastic Thyroid Cancer\nBiomarkers: TSC2 oncogenic variants [present]\nTherapy: Everolimus\nTherapy approach: Monotherapy\nTherapy strategy: PI3K/AKT/mTOR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf\nPublication date: 2022-02-01",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).\nCancer type: Prostate Adenocarcinoma\nBiomarkers: CDK12 pathogenic variants [present]\nTherapy: Enzalutamide + Talazoparib\nTherapy approach: Combination therapy\nTherapy strategy: Antiandrogen + PARP inhibition\nTherapy type: Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf\nPublication date: 2024-02-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Osimertinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Osimertinib\nTherapy approach: Monotherapy\nTherapy strategy: EGFR inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\nPublication date: 2024-09-25",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Lazertinib + Amivantamab\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + EGFR inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\nPublication date: 2024-09-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Lazertinib + Amivantamab\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + EGFR inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\nPublication date: 2024-09-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Lazertinib + Amivantamab\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + EGFR inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf\nPublication date: 2024-08-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Lazertinib + Amivantamab\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + EGFR inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf\nPublication date: 2024-08-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR Exon 19 (Deletion) [present]\nTherapy: Amivantamab + Carboplatin + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + Platinum-based chemotherapy + Antifolate\nTherapy type: Targeted therapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\nPublication date: 2024-09-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: EGFR p.L858R [present]\nTherapy: Amivantamab + Carboplatin + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: EGFR inhibition + Platinum-based chemotherapy + Antifolate\nTherapy type: Targeted therapy + Chemotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\nPublication date: 2024-09-19",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.\nCancer type: Ovarian Epithelial Tumor\nBiomarkers: FOLR1 positive [present]\nTherapy: Mirvetuximab soravtansine\nTherapy approach: Monotherapy\nTherapy strategy: Folate receptor-alpha inhibition\nTherapy type: Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf\nPublication date: 2024-03-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.\nCancer type: High-Grade Serous Fallopian Tube Cancer\nBiomarkers: FOLR1 positive [present]\nTherapy: Mirvetuximab soravtansine\nTherapy approach: Monotherapy\nTherapy strategy: Folate receptor-alpha inhibition\nTherapy type: Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf\nPublication date: 2024-03-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.\nCancer type: Peritoneal Serous Carcinoma\nBiomarkers: FOLR1 positive [present]\nTherapy: Mirvetuximab soravtansine\nTherapy approach: Monotherapy\nTherapy strategy: Folate receptor-alpha inhibition\nTherapy type: Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf\nPublication date: 2024-03-22",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Low-Grade Glioma, NOS\nBiomarkers: BRAF rearrangements [present]\nTherapy: Tovorafenib\nTherapy approach: Monotherapy\nTherapy strategy: B-RAF inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf\nPublication date: 2024-04-23",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Low-Grade Glioma, NOS\nBiomarkers: v::BRAF [present]\nTherapy: Tovorafenib\nTherapy approach: Monotherapy\nTherapy strategy: B-RAF inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf\nPublication date: 2024-04-23",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Low-Grade Glioma, NOS\nBiomarkers: BRAF p.V600E [present]\nTherapy: Tovorafenib\nTherapy approach: Monotherapy\nTherapy strategy: B-RAF inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf\nPublication date: 2024-04-23",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Low-Grade Glioma, NOS\nBiomarkers: BRAF p.V600K [present]\nTherapy: Tovorafenib\nTherapy approach: Monotherapy\nTherapy strategy: B-RAF inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf\nPublication date: 2024-04-23",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN\n(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Durvalumab + Paclitaxel\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Taxane-based chemotherapy\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN\n(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Cisplatin + Durvalumab + Gemcitabine\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Antimetabolite\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN\n(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Cisplatin + Durvalumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN\n(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Durvalumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\nPublication date: 2024-08-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib in combination with cetuximab for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) and that continued approval for this indications may be contingent upon verification and description of a clinical benefit in confirmatory trials.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: KRAS p.G12C [present]\nTherapy: Adagrasib + Cetuximab\nTherapy approach: Combination therapy\nTherapy strategy: RAS inhibition + EGFR inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf\nPublication date: 2022-12-12",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH1 p.R132C [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH1 p.R132G [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH1 p.R132H [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH1 p.R132L [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH1 p.R132S [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH2 p.R172K [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH2 p.R172M [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH2 p.R172G [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH2 p.R172S [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Astrocytoma\nBiomarkers: IDH2 p.R172W [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH1 p.R132C [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH1 p.R132G [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH1 p.R132H [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH1 p.R132L [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH1 p.R132S [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH2 p.R172K [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH2 p.R172M [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH2 p.R172G [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH2 p.R172S [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.\nCancer type: Oligodendroglioma\nBiomarkers: IDH2 p.R172W [present]\nTherapy: Vorasidenib\nTherapy approach: Monotherapy\nTherapy strategy: IDH1/2 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf\nPublication date: 2024-08-06",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Anastrozole + Goserelin + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + Gonadotropin-releasing hormone (GnRH) agonist + CDK4/6 inhibition\nTherapy type: Hormone therapy + Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Anastrozole + Goserelin + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + Gonadotropin-releasing hormone (GnRH) agonist + CDK4/6 inhibition\nTherapy type: Hormone therapy + Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Anastrozole + Goserelin + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Aromatase inhibition + Gonadotropin-releasing hormone (GnRH) agonist + CDK4/6 inhibition\nTherapy type: Hormone therapy + Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Goserelin + Letrozole + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Gonadotropin-releasing hormone (GnRH) agonist + Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Goserelin + Letrozole + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Gonadotropin-releasing hormone (GnRH) agonist + Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Goserelin + Letrozole + Ribociclib\nTherapy approach: Combination therapy\nTherapy strategy: Gonadotropin-releasing hormone (GnRH) agonist + Aromatase inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Hormone therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf\nPublication date: 2024-09-17",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Cisplatin + Nivolumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Cisplatin + Gemcitabine + Nivolumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + Antimetabolite + PD-1/PD-L1 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Ipilimumab + Nivolumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + CTLA-4 inhibition + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Cisplatin + Ipilimumab + Nivolumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + CTLA-4 inhibition + PD-1/PD-L1 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Ipilimumab + Nivolumab + Paclitaxel\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + CTLA-4 inhibition + PD-1/PD-L1 inhibition + Taxane-based chemotherapy\nTherapy type: Chemotherapy + Immunotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: dMMR [present]\nTherapy: Ipilimumab + Nivolumab\nTherapy approach: Combination therapy\nTherapy strategy: CTLA-4 inhibition + PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: MSI-H [present]\nTherapy: Nivolumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: dMMR [present]\nTherapy: Nivolumab\nTherapy approach: Monotherapy\nTherapy strategy: PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PIK3CA somatic variants [present]\nTherapy: Fulvestrant + Inavolisib + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + PI3K/AKT/mTOR inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf\nPublication date: 2024-10-10",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\nTherapy: Fulvestrant + Inavolisib + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + PI3K/AKT/mTOR inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf\nPublication date: 2024-10-10",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present], PIK3CA somatic variants [present]\nTherapy: Fulvestrant + Inavolisib + Palbociclib\nTherapy approach: Combination therapy\nTherapy strategy: Estrogen receptor inhibition + PI3K/AKT/mTOR inhibition + CDK4/6 inhibition\nTherapy type: Hormone therapy + Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf\nPublication date: 2024-10-10",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive, as determined by an FDA-approved test. The package insert states that that eligible patients should have CLDN18.2 positive tumors, defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining. The package insert further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).\nCancer type: Adenocarcinoma of the Gastroesophageal Junction\nBiomarkers: HER2-negative [present], CLDN18.2 >= 75% [present]\nTherapy: Fluorouracil + Oxaliplatin + Zolbetuximab\nTherapy approach: Combination therapy\nTherapy strategy: Thymidylate synthase inhibition + Platinum-based chemotherapy + CLDN18.2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf\nPublication date: 2024-10-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive, as determined by an FDA-approved test. The package insert states that that eligible patients should have CLDN18.2 positive tumors, defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining. The package insert further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).\nCancer type: Adenocarcinoma of the Gastroesophageal Junction\nBiomarkers: HER2-negative [present], CLDN18.2 >= 75% [present]\nTherapy: Capecitabine + Oxaliplatin + Zolbetuximab\nTherapy approach: Combination therapy\nTherapy strategy: Thymidylate synthase inhibition + Platinum-based chemotherapy + CLDN18.2 inhibition\nTherapy type: Chemotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf\nPublication date: 2024-10-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Intraductal Papillary Neoplasm of the Bile Duct\nBiomarkers: HER2-positive [present]\nTherapy: Zanidatamab\nTherapy approach: Monotherapy\nTherapy strategy: ER signaling inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf\nPublication date: 2024-11-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Intracholecystic Papillary Neoplasm\nBiomarkers: HER2-positive [present]\nTherapy: Zanidatamab\nTherapy approach: Monotherapy\nTherapy strategy: ER signaling inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf\nPublication date: 2024-11-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Cholangiocarcinoma\nBiomarkers: HER2-positive [present]\nTherapy: Zanidatamab\nTherapy approach: Monotherapy\nTherapy strategy: ER signaling inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf\nPublication date: 2024-11-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::NRG1 [present]\nTherapy: Zenocutuzumab\nTherapy approach: Monotherapy\nTherapy strategy: NRG1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf\nPublication date: 2024-12-04",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).\nCancer type: Pancreatic Adenocarcinoma\nBiomarkers: v::NRG1 [present]\nTherapy: Zenocutuzumab\nTherapy approach: Monotherapy\nTherapy strategy: NRG1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf\nPublication date: 2024-12-04",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to ensartinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ALK [present]\nTherapy: Ensartinib\nTherapy approach: Monotherapy\nTherapy strategy: ALK inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf\nPublication date: 2024-12-18",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Furthermore, it states that encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: BRAF p.V600E [present]\nTherapy: Fluorouracil + Cetuximab + Encorafenib + Oxaliplatin\nTherapy approach: Combination therapy\nTherapy strategy: Thymidylate synthase inhibition + EGFR inhibition + B-RAF inhibition + Platinum-based chemotherapy\nTherapy type: Chemotherapy + Targeted therapy + Targeted therapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf\nPublication date: 2024-12-20",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).\nCancer type: Chronic Myelogenous Leukemia\nBiomarkers: BCR::ABL1 [present]\nTherapy: Asciminib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\nPublication date: 2024-10-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). The package insert states that this indication is approved under accelerated approval based on major molecular response rate and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).\nCancer type: Chronic Myeloid Leukemia, BCR-ABL1+\nBiomarkers: BCR::ABL1 [present]\nTherapy: Asciminib\nTherapy approach: Monotherapy\nTherapy strategy: BCR-ABL inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\nPublication date: 2024-10-29",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Durvalumab + Tremelimumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + CTLA-4 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf\nPublication date: 2022-11-10",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Cisplatin + Durvalumab + Tremelimumab + Pemetrexed\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + CTLA-4 inhibition + Antifolate\nTherapy type: Chemotherapy + Immunotherapy + Immunotherapy + Chemotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf\nPublication date: 2022-11-10",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Durvalumab + Gemcitabine + Tremelimumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Antimetabolite + CTLA-4 inhibition\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf\nPublication date: 2022-11-10",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Cisplatin + Durvalumab + Gemcitabine + Tremelimumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Antimetabolite + CTLA-4 inhibition\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf\nPublication date: 2022-11-10",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: Wild type ALK [present], Wild type EGFR [present]\nTherapy: Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab\nTherapy approach: Combination therapy\nTherapy strategy: Platinum-based chemotherapy + PD-1/PD-L1 inhibition + Taxane-based chemotherapy + CTLA-4 inhibition\nTherapy type: Chemotherapy + Immunotherapy + Chemotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf\nPublication date: 2022-11-10",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.\nCancer type: Acute Lymphoid Leukemia\nBiomarkers: t(KMT2A;v) [present]\nTherapy: Revumenib\nTherapy approach: Monotherapy\nTherapy strategy: Menin inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf\nPublication date: 2024-11-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.\nCancer type: Acute Myeloid Leukemia\nBiomarkers: t(KMT2A;v) [present]\nTherapy: Revumenib\nTherapy approach: Monotherapy\nTherapy strategy: Menin inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf\nPublication date: 2024-11-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.\nCancer type: Burkitt Lymphoma\nBiomarkers: t(KMT2A;v) [present]\nTherapy: Revumenib\nTherapy approach: Monotherapy\nTherapy strategy: Menin inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf\nPublication date: 2024-11-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.\nCancer type: Acute Leukemias of Ambiguous Lineage\nBiomarkers: t(KMT2A;v) [present]\nTherapy: Revumenib\nTherapy approach: Monotherapy\nTherapy strategy: Menin inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf\nPublication date: 2024-11-15",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Letrozole\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Anastrozole\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Abemaciclib + Anastrozole\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Anastrozole\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Exemestane\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: ER positive [present], HER2-negative [present]\nTherapy: Abemaciclib + Exemestane\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).\nCancer type: Invasive Breast Carcinoma\nBiomarkers: HER2-negative [present], PR positive [present]\nTherapy: Abemaciclib + Exemestane\nTherapy approach: Combination therapy\nTherapy strategy: CDK4/6 inhibition + Aromatase inhibition\nTherapy type: Targeted therapy + Hormone therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\nPublication date: 2023-03-03",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.\nCancer type: Colorectal Adenocarcinoma\nBiomarkers: MSI-H [present]\nTherapy: Ipilimumab + Nivolumab\nTherapy approach: Combination therapy\nTherapy strategy: CTLA-4 inhibition + PD-1/PD-L1 inhibition\nTherapy type: Immunotherapy + Immunotherapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\nPublication date: 2025-04-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted approval to taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The package insert instructs to select patients based on the presence of ROS1 rearrangements in tumor specimen(s).\nCancer type: Non-Small Cell Lung Cancer\nBiomarkers: v::ROS1 [present]\nTherapy: Taletrectinib\nTherapy approach: Monotherapy\nTherapy strategy: NTRK inhibition + ROS1 inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf\nPublication date: 2025-06-11",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin, a c-Met-directed antibody and microtubule inhibitor conjugate, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).\nCancer type: Lung Non-Squamous Non-Small Cell Carcinoma\nBiomarkers: c-Met >= 50% [present]\nTherapy: Telisotuzumab Vedotin\nTherapy approach: Monotherapy\nTherapy strategy: MET inhibition\nTherapy type: Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf\nPublication date: 2025-05-14",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This approval is based on RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). 44% of patients responded (3.5% with complete response, 40% with partial response), and the package insert notes that the tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.\nCancer type: Low-Grade Serous Ovarian Cancer\nBiomarkers: KRAS p.G12C [present]\nTherapy: Avutometinib + Defactinib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + RAF inhibition + FAK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf\nPublication date: 2025-05-08",
  "Approval status: Regulatory approval (fda)\nIndication: The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This approval is based on RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). 44% of patients responded (3.5% with complete response, 40% with partial response), and the package insert notes that the tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.\nCancer type: Low-Grade Serous Ovarian Cancer\nBiomarkers: KRAS p.G12V [present]\nTherapy: Avutometinib + Defactinib\nTherapy approach: Combination therapy\nTherapy strategy: MEK inhibition + RAF inhibition + FAK inhibition\nTherapy type: Targeted therapy + Targeted therapy\nApproval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf\nPublication date: 2025-05-08"
]